PRO-C16
A fragment of the C-terminal domain of type XVI FACIT collagen, enabling non-invasive monitoring of extracellular matrix remodeling and fibrostenotic activity in gastrointestinal disorders such as colorectal cancer and Crohn’s disease.
Key features and values
- Quantifies type XVI collagen fragments associated with extracellular matrix remodeling.
- Reflects fibrostenotic activity in gastrointestinal disorders, including colorectal cancer and Crohn’s disease.
- Provides a non-invasive measure of extracellular matrix dynamics.
- Supports monitoring of disease progression and response to therapies targeting fibrosis.
- Applicable in research on diseases characterized by aberrant extracellular matrix turnover.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The PRO-C16 biomarker assay measures specific fragments of the C-terminal domain of type XVI FACIT collagen, serving as an indicator of extracellular matrix remodeling and fibrostenotic activity in gastrointestinal disorders. This non-invasive assay provides insights into tissue remodeling processes associated with conditions such as colorectal cancer and Crohn’s disease. By quantifying type XVI collagen degradation products, the PRO-C16 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue fibrosis and damage. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover and fibrotic tissue remodeling.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
